$JAGX

Jaguar Health (JAGX) announced its subsidiary Napo Pharmaceuticals is providing crofelemer for compassionate use in an infant with intestinal failure due to congenital sodium diarrhea. The company aims to file an NDA for crofelemer to treat microvillus inclusion disease (MVID) in mid-2027. Clinical trials show reductions in parenteral support needs for pediatric patients with MVID and short bowel syndrome with IF (SBS-IF).

Several biotech stocks are trading higher in premarket, including Autonomix Medical (AMIX) up 29% at $6.92, Picard Medical (PMI) up 12% at $5.85, and others. The gains indicate early momentum and potential volatility for the trading day, according to the market activity.

Jaguar Health (JAGX) reported Q2 2026 earnings, highlighting clinical progress in rare disease programs. CEO Lisa Conte noted significant reductions in parenteral support for patients with MVID and SBS-IF. The company aims to file an NDA for MVID in Q2 2027 and seeks a commercialization partner. Revenue fell 60% YoY to $1.2M due to a licensing deal, but operating loss decreased by $400K. Crofelemer's IP status provides long-term exclusivity.

Jaguar Health (NASDAQ:JAGX) reported Q2 2026 financials, showing a 59% revenue decline to $1.2M and a net loss of $12.7M. The company is focused on developing crofelemer for rare intestinal diseases, with a planned NDA submission in Q2 2027. Non-GAAP recurring EBITDA loss was $8.4M, a 6% increase from the prior year. Jaguar will host an investor webcast on August 19, 2026, to discuss results and updates.

Jaguar Health, Inc. (JAGX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Jaguar Health Reports Second Quarter 2026 Financials Company remains sharply focused on its ongoing global development program for crofelemer for rare intestinal failure (IF) diseases; as announced , presentation at ESPGHAN 2026 described additional groundbreaking re

Jaguar Health (NASDAQ:JAGX) reported exploratory survey results supporting Neonorm Dog, a plant-based, non-prescription digestive support product for dogs. Surveys of 33 veterinary oncologists and 18 dog owners showed high perceived clinical relevance and purchase intent. Jaguar expects to launch Neonorm Dog via Amazon and Chewy after packaging and labeling preparations.

Jaguar Health (NASDAQ:JAGX) said exploratory surveys of 33 veterinary oncologists and 18 dog owners support the commercial potential of Neonorm Dog, a plant-based, non-prescription supplement for normal stool consistency and GI fluid balance. Jaguar reported nearly 90% of oncologists found it clinically relevant and almost 80% would likely recommend it for selected patients. Launch prep is underway, with planned sales via Amazon and Chewy.

Jaguar Health, Inc. (JAGX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 d144017dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 Certain identified information marked as [****] has been excluded from this exhibit because it both (i) is not material and (ii) is the type that the Company treats as private or confidential. MANUFACTURING AND SUPPLY AGREE

Jaguar Health, Inc. (JAGX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. 8-K false 0001585608 0001585608 2026-06-22 2026-06-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22,

Jaguar Health, Inc. (JAGX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. 8-K false 0001585608 0001585608 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17,